Advertisement

Abdominal giant lymph node hyperplasia (Castleman’s disease): report of two cases

Case Report
  • 36 Downloads

Abstract

Objective

To describe the clinical characteristics and diagnostic features of giant lymph node hyperplasia or Castleman’s disease found in rare locations.

Methods

Two cases of Castleman’s disease (1 abdominal and 1 retroperitoneal) were confirmed histopathologically. The clinical and medical imaging features were described and relative literatures were reviewed.

Results

One patient had no clinical symptoms and the other had epigastric discomfort. The location of the benign tumor was retroperitoneal and left adrenal gland, respectively. Both cases were of solitary tumor, 1 was a hyaline-vascular type and the other was a mixed type with plasma cell and hyaline-vascular type. Both were successfully treated by surgical excision. Patients were followed up for 3 and 4 years respectively with no signs of recurrence on CT imaging.

Conclusions

Abdominal Castleman’s disease lacks specific clinical manifestations. Definitive diagnosis requires histologic examination and excisional surgery is the method of choice for treatment.

Keywords

Giant lymph node hyperplasia Castleman’s disease Diagnosis CT imaging Surgery 

References

  1. [1]
    Castleman B., Iverson L., Menedez V.P. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer., 1956, 9, 822–830PubMedCrossRefGoogle Scholar
  2. [2]
    Bhatti M. A.K., Ferrante J.W., Gielchinsky I., Norman J.C. Giant lymph node hyperplasia of the mediastinum (castleman’s disease): case report and review. Tex Heart Inst J., 1984, 11: 378–384PubMedGoogle Scholar
  3. [3]
    Kim J. H., Jun T.G., Sung S.W., Shim Y.S., Han S.K., Kim Y.W., Yoo C.G., Seo J.W., Rho J.R. Giant lymph node hyperplasia (Castleman’s disease) in the chest. Ann Thorac Surg., 1995, 59: 1162–1165PubMedCrossRefGoogle Scholar
  4. [4]
    Seirafi P. A., Ferguson E., Edwards F.H. Thoracoscopic resection of Castleman disease: case report and review. Chest., 2003, v123:280–282PubMedCrossRefGoogle Scholar
  5. [5]
    Bandera B., Ainsworth C., Shikle J., Rupard E., Roach M. Treatment of unicentric castleman disease with neoadjuvant rituximab. Chest., 2010, 138: 1239–1241PubMedCrossRefGoogle Scholar
  6. [6]
    Rena O., Casadio C., Maggi G. Castleman’s disease: unusual intrathoracic localization Eur J Cardiothorac Surg., 2001, 19, 519–521.PubMedCrossRefGoogle Scholar
  7. [7]
    Weisenburger D. D., Nathwani B.N., Winberg C.D., Rappaport H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol., 1985,16:162–172PubMedCrossRefGoogle Scholar
  8. [8]
    Slotwiner A., Garwacki C.P., Moll S. Castleman’s disease. Am J Hematol., 2003,73:64–65PubMedCrossRefGoogle Scholar
  9. [9]
    McAdams H. P., Rosado-de-Christenson M.R., Fishback N.F., Templeton P.A. Castleman disease Of the thorax: radiologic features with clinical and histopatholigic correlation. Radiology., 1998, 209, 221–228PubMedGoogle Scholar
  10. [10]
    Kim M. H., Hwang S., Choi Y.B., Oh S.T., Kim S.C., Choi G.M., Ahn C.S., Kim K.H., Moon D.B., Ha T.Y., Song G.W., Jung D.H., Yu E.S., Lee S.G. Castleman disease of the abdomen—single-center experience of 13 surgically treated patients over 11 years. Hepato-Gastroenterol., 2010, 57, 1060–1063Google Scholar
  11. [11]
    Dispenzieri A., Gertz M.A. Treatment of Castleman’s disease. Curr Treat Options Oncol., 2005, 6, 255–266PubMedCrossRefGoogle Scholar
  12. [12]
    Chronowski G. M., Ha C.S., Wilder R.B., Cabanillas F., Manning J., Cox J.M. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001, 92, 670.PubMedCrossRefGoogle Scholar
  13. [13]
    Powles T., Stebbing J., Bazeos A., Hatzimichael, E., Mandalia, S., Nelson, M., Gazzard, B., Bower, M. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol., 2009, 20, 775–779PubMedCrossRefGoogle Scholar
  14. [14]
    van Rhee F., Fayad L., Voorhees P., Furman R., Lonial S., Borghaei H., Sokol L., Crawford J., Cornfeld M., Qi M., Qin X., Herring J., Casper C., Kurzrock R. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol., 2010, 28, 3701–3708PubMedCrossRefGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Division of UltrasoundLiaocheng People’s Hospital and Liaocheng Clinical School of Taishan Medical UniversityLiaocheng, ShandongP. R. China
  2. 2.Shandong Provincial Medical Imaging Research InstituteJinan, ShandongP. R. China
  3. 3.School of Biomedical SciencesCharles Sturt UniversityWagga WaggaAustralia

Personalised recommendations